Evaluation of size-based distribution of components in VYXEOS® liposomal formulation using asymmetric flow field-flow fractionation
Journal of Chromatography A · 2024-12 · 1738 · 465488
DOI: 10.1016/j.chroma.2024.465488 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chromatography A, 2024-12. Verfasst von Dumindika A Siriwardane und 3 weiteren Autor:innen. Beteiligte Einrichtung: Arkansas Laboratory, Office of Regulatory Science, Office of Regulatory Affairs, U.S. Food and Drug Administration, Jefferson, AR 72079, United State…. Hauptthemen laut MEDLINE: Liposomes, Fractionation, Field Flow, Daunorubicin, Particle Size. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: U.S. Department of Energy, Oklahoma Restaurant Association, U.S. Food and Drug Administration.
Abstract (Originalsprache)
VYXEOS® is the first FDA-approved dual-API liposomal formulation containing two different chemotherapeutics, daunorubicin and cytarabine at a 1:5 molar ratio. Analysis of bulk formulation does not provide insight to size-based distribution of APIs and excipients, therefore asymmetrical flow field-flow fractionation (AF4) was utilized for the size-based separation of VYXEOS® liposomes and collected size fractions were further analyzed for the concentrations of APIs, lipid excipients, and copper. Analysis results revealed a significant variation in API distribution across the size fractions, with the larger liposomes encapsulating a higher ratio of cytarabine to daunorubicin compared to the smaller liposomes, while lipid excipient composition was held constant across the size range. We attribute the size-based variation of API ratios to structural change during API loading and sequence of API loading. Cytarabine is first passively loaded into liposomes containing copper gluconate, and then daunorubicin is actively loaded using copper gradient where the daunorubicin is retained in the liposomes as a copper complex. This method can be extended to characterize various single and dual-API liposomal nanocarriers during drug product development and/or post market quality control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Arkansas Laboratory, Office of Regulatory Science, Office of Regulatory Affairs, U.S. Food and Drug Administration, Jefferson, AR 72079, United States.
- Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food, and Drug Administration, Silver Spring, MD 20993, United States. Electronic address: Wenlei.Jiang@fda.hhs.go…
- Arkansas Laboratory, Office of Regulatory Science, Office of Regulatory Affairs, U.S. Food and Drug Administration, Jefferson, AR 72079, United States. Electronic address: Thilak.Mudalige@fda.hhs.gov.
Förderung
- U.S. Department of Energy
- Oklahoma Restaurant Association
- U.S. Food and Drug Administration
- Office of Regulatory Affairs
- Center for Drug Evaluation and Research
- Oak Ridge Institute for Science and Education
Zitieren
APA
Siriwardane, D. A., Shakiba, S., Jiang, W., & Mudalige, T. (2024). Evaluation of size-based distribution of components in VYXEOS® liposomal formulation using asymmetric flow field-flow fractionation. Journal of Chromatography A, 1738, 465488. https://doi.org/10.1016/j.chroma.2024.465488
Vancouver
Siriwardane DA, Shakiba S, Jiang W, Mudalige T. Evaluation of size-based distribution of components in VYXEOS® liposomal formulation using asymmetric flow field-flow fractionation. Journal of Chromatography A. 2024;1738:465488. doi:10.1016/j.chroma.2024.465488
BibTeX
@article{Siriwardane2024,
author = {Siriwardane, Dumindika A and Shakiba, Sheyda and Jiang, Wenlei and Mudalige, Thilak},
title = {Evaluation of size-based distribution of components in VYXEOS® liposomal formulation using asymmetric flow field-flow fractionation},
journal = {Journal of Chromatography A},
year = {2024},
volume = {1738},
pages = {465488},
doi = {10.1016/j.chroma.2024.465488}
}
EUVIMED